Determination of the methylation status of MGMT in different regions within glioblastoma multiforme

被引:0
作者
Mark G. Hamilton
Gloria Roldán
Anthony Magliocco
John B. McIntyre
Ian Parney
Jacob C. Easaw
机构
[1] University of Calgary,Division of Neurosurgery, Department of Clinical Neurosciences
[2] Tom Baker Cancer Centre,Department of Oncology
[3] Alberta Cancer Board,Department of Neurologic Surgery
[4] Mayo Clinic,undefined
来源
Journal of Neuro-Oncology | 2011年 / 102卷
关键词
MGMT; Methylation; GBM; Glioblastoma; Brain tumor; Homogeneity; Heterogeneity;
D O I
暂无
中图分类号
学科分类号
摘要
Epigenetic silencing of the MGMT gene through promoter methylation correlates with improved survival in Glioblastoma Multiforme (GBM) patients receiving concurrent chemoradiotherapy. Although the clinical benefit is primarily seen in patients with methylated MGMT promoter, some unmethylated patients also respond to Temozolomide. One possible explanation may be intratumoral heterogeneity. This study was designed to assess the methylation status of the MGMT promoter in different areas of GBM and determine if methylation status varied depending on the fixation technique (paraffin-embedding versus fresh frozen) used to store tissue. Using intraoperative navigation, biopsies were obtained from three distinct regions: the enhancing outer area, the non-enhancing inner core, and an area immediately outside the enhancing region. Only patients with GBM were included for evaluation and analysis. Samples taken from each area were divided with half stored by flash freezing and the other half stored using paraffin fixation. Methylation Specific-PCR (MS-PCR) was used for analysis of MGMT promoter methylation. Thirteen patients were included. Ten were male with a median age of 62 years. In each patient, samples were taken from the enhancing rim and the necrotic centre. However, it was not considered safe or feasible to obtain samples from the area immediately adjacent to the enhancing tumor rim in one case. All patients were homogeneous for methylation status throughout their tumor and tissue taken adjacent to it when frozen tissue was used. However, four patients had discrepancies in the MGMT promoter status between the frozen and paraffin-embedded blocks and one patient was not homogeneous within the tumor when paraffin-embedded tissue was used. MGMT promoter methylation status was homogeneous in all GBM tumors. Our observation that methylation status varied depending if the DNA was extracted from paraffin-embedded versus frozen tissue is concerning. Although the reason for this is unclear, we postulate that the timing from resection to fixation or the process of fixation itself may potentially alter methylation status in paraffin-embedded tumors.
引用
收藏
页码:255 / 260
页数:5
相关论文
共 68 条
[1]  
Stupp R(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-996
[2]  
Mason WP(2000)Survival of human glioma cells treated with various combination of temozolomide and X-rays Int J Radiat Oncol Biol Phys 47 779-784
[3]  
van den Bent MJ(1997)In vitro evaluation of temozolomide combined with X-irradiation Anticancer Drugs 8 92-97
[4]  
van Rijn J(2002)Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase Cancer Res 62 1915-1919
[5]  
Heimans JJ(2005)MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997-1003
[6]  
van den Berg J(1996)Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea Cancer Res 56 5375-5379
[7]  
van der Valk P(2000)Apoptosis induced by DNA damage O6-methylguanine is bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent Cancer Res 60 5815-5824
[8]  
Slotman BJ(2000)Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 1350-1354
[9]  
Wedge SR(2004)Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide Clin Cancer Res 10 1871-1874
[10]  
Porteous JK(2008)Heterogeneity of human glioblastoma: Glutathione-S-transferase and methylguanine-methyltransferase Cancer Invest 26 597-609